GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » Valuation Rank

Quanterix (Quanterix) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Quanterix Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Quanterix Valuation Rank Related Terms

Thank you for viewing the detailed overview of Quanterix's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Quanterix (Quanterix) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlesex Turnpike, Billerica, MA, USA, 01821
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Executives
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly director C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram officer: Chief Financial Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser director 561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle officer: CFO and Treasurer C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue officer: President, Quanterix & Dx C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka director 2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
John J Fry officer: General Counsel & Secretary 8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky director, officer: EC, President & CEO 68 ELM STREET, HOPKINTON MA 01748
Karen Flynn director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy officer: SVP R&D and CTO C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon officer: Sr VP, Stgc Mrktg & Assay Tech 113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421